Feature Revive readies key clinical studies in gout and kidney stones By Len Zehr Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. “We believe that the... March 1, 2016